|
Lobular Breast Cancer
|
|
15
|
4518
|
7 October 2025
|
|
Help us shape our input into Scotland’s National Advisory Medicine Group (NCMAG) Programme review of the proposed use of paclitaxel in combination with pertuzumab and trastuzumab
|
|
0
|
38
|
3 October 2025
|
|
Fluid on lung
|
|
3
|
211
|
2 October 2025
|
|
Nephrostomy advice
|
|
8
|
184
|
30 September 2025
|
|
Paclitaxel reaction
|
|
7
|
192
|
28 September 2025
|
|
Breast Surgery for Triple Positive MBC
|
|
0
|
73
|
24 September 2025
|
|
Constant vomiting
|
|
25
|
940
|
19 September 2025
|
|
Travel advice
|
|
14
|
427
|
19 September 2025
|
|
Long term Herceptin patients
|
|
9
|
291
|
17 September 2025
|
|
Cryotherapy with topicals
|
|
1
|
76
|
16 September 2025
|
|
Drug SEs
|
|
3
|
341
|
18 August 2025
|
|
German clinics
|
|
31
|
9015
|
16 August 2025
|
|
Have you received capivasertib with fulvestrant?
|
|
1
|
246
|
31 July 2025
|
|
Brain met, surgery, SRS now Docetaxel & Phesgo
|
|
4
|
448
|
26 July 2025
|
|
Lump in axilla
|
|
3
|
291
|
21 July 2025
|
|
Capecitabine tablets and swallowing
|
|
2
|
195
|
18 July 2025
|
|
New bone mets-what next
|
|
5
|
831
|
17 July 2025
|
|
Holistic healing
|
|
42
|
2122
|
14 July 2025
|
|
Nuclear bone scan results
|
|
4
|
2490
|
5 July 2025
|
|
We’re looking for people to help shape our response to the Scottish Medicines Consortium’s (SMC) appraisal of elacestrant (korserdu) for treating ER positive, HER-2 negative secondary breast cancer with an ESR1 mutation
|
|
0
|
83
|
2 July 2025
|
|
Xeloda capecitabine weight gain
|
|
10
|
1713
|
15 June 2025
|
|
Liver misbehaving
|
|
2
|
456
|
15 June 2025
|
|
Elevated CA153 along with new elevated CA125
|
|
9
|
444
|
30 May 2025
|
|
Treatment advice
|
|
1
|
247
|
25 May 2025
|
|
We're looking for people to help shape our response to the Scottish Medicines Consortium's appraisal of capivasertib in combination with fulvestrant for treating hormone receptor positive, HER-2 negative secondary breast cancer after endocrine therapy
|
|
0
|
86
|
22 May 2025
|
|
We’re looking for people to shape our response to NICE’s appraisal for inavolisib (Itovebi) with palbociclib & fulvestrant for treating recurrent HR-positive, HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment
|
|
0
|
142
|
15 May 2025
|
|
Cbd oil and cancer
|
|
12
|
30350
|
5 May 2025
|
|
Help us fix the drugs system - share your experience
|
|
1
|
209
|
29 April 2025
|
|
Three monthly denosumab injections
|
|
6
|
398
|
18 April 2025
|
|
Immunotherapy alone
|
|
2
|
347
|
10 April 2025
|